Teva Has A New Near-Term Opportunity With Subcutaneous Risperidone

A Phase III trial for an extended-release subcutaneously administered version of the antipsychotic risperidone was positive in patients with schizophrenia.

Subcutaneous injection — Teva hopes to bring a subcutaneous risperidone to market • Source: Shutterstock

Teva Pharmaceutical Industries Ltd., which has been in recovery mode for several years, could have a near-term commercial opportunity with an extended-release, subcutaneously administered formula of the antipsychotic risperidone. A Phase III clinical trial evaluating the efficacy of TV-46000 as a treatment for schizophrenia was positive, the company announced on 7 January.

Only top-line data were released, but the subcutaneous version of a long-acting form of risperidone demonstrated a delay in time to relapse at a monthly dose and when dosed once every two months

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.